Iris Finance转发了
hims & hers had a monster day yesterday, popping >20% on continued momentum after reporting a 4x increase in EBITDA and +77% in sales YoY in their latest earnings. Hims continues to be a masterful display of the DTC business model at scale. Let’s break down the report ???? 1/ Subscribers HIMS is special because of its subscriber growth & retention combo. Unlike most DTC brands, Hims retains its customers for years. For reference, the average percentage of customers retained by brands on Iris after 90 days is 12%. In the quarter, subscribers grew +44% YoY to 2.05 million. ?? 1Q23 subscribers: 1.2 million ?? 3Q24 subscribers: 2 million What’s more, those subscriber economics are improving meaningfully. Monthly revenue per subscriber: ?? 3Q23: $54 ?? 4Q23: $67 Meanwhile, overall AOV was up a whopping 48%, with revenue surpassing $1 billion! Acquiring more subscribers is driving growth, which is great. But simultaneously improving unit economics is a whole other ball game. This team is executing beautifully. 2/ Gross Margins Obviously, there is a lot of hype around GLP-1s, and in the release, HIMS announced that they would launch Liraglutide in 2025, another GLP-1. These products carry lower margin profiles, so we’ve seen HIMS’ gross margin contract almost 4 points in less than a year. Usually, this would be highly concerning. However, this is a first-world problem; if the company’s lower-margin products are driving relative marketing efficiencies on a per-order basis, so be it. ?? 4Q23 gross margin: 83% ?? 3Q24 gross margin: 79% 3/ Marketing As HIMS grows revenue, gross margins are going down, but profitability is going up. Typically, MER (Marketing Efficiency Ratio) increases come with spend decreases. What's wild here is that they’re spending more, with higher MERs, lower gross margins, and getting more contribution. 4/ Profitability All of these factors aligning is what is driving profound increases in EBITDA, up 4x YoY. This is driving massive increases in cash flow. The stock trades nicely right now at around 20x annualized free cash flow or 4x sales. I had priced the stock at $27.02 right after the earnings report, which it jumped to yesterday, so we're fairly priced again. In Summary: $HIMS continues to prove that it is a critical distribution node for modern advancements in medicine as it continues to attract high-quality subscribers. HIMS has a SaaS-esque business model in a huge TAM. Weight loss alone is a $530 billion market. $HIMS revenue is $1.5 billion. On Friday, we will be doing the full $HIMS deep-dive breakdown, and as always, I will be providing the data I used to perform the analysis. If you want to sharpen your finance mind, make sure you SUBSCRIBE to the link pinned to my profile ??